Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and Palatin Technologies, Inc. (NYSEMKT:PTN) have signed an agreement which will see the two firms share rights for the development and commercialization of Rekynda in North America.

Rekynda is a product made with the purpose of treating a sexual disorder in pre-menopausal women known as hypoactive sexual desire disorder. Two Phase III trials of the drug have already been completed and by next year, it will be in the hands of the Food and Drug Administration.

merger, businessman, greeting, handshake, hands, business, concept, handclasp, success, friendship, symbol, partnership, tone, cooperation, people, agree, welcome,

Kritchanut/Shutterstock.com

Advance Payment

The deal will see AMAG fork out $60 million to Palatin Technologies, Inc. (NYSEMKT:PTN) in advance. AMAG will also pay an extra $380 million if particular milestones on the regulatory and sales sides are met. Also, Palatin Technologies, Inc. (NYSEMKT:PTN) will be reimbursed about $25 million by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to cater for development expenses.

If all goes according to plan, Rekynda’s new drug application filing will be filed in 2018. It is also anticipated that the drug could be approved and launched a year after the filing.

“AMAG is excited to expand its women’s health portfolio with a product that could address a compelling medical problem that currently is under-addressed,” said AMAG Pharmaceutical’s chief executive officer, William Heiden.

Follow Amag Pharmaceuticals Inc. (NASDAQ:AMAG)
Trade (NASDAQ:AMAG) Now!

Hypoactive Sexual Desire Disorder

The disorder that the drug aims to treat, HSDD, is one of the most common of sexual dysfunctions in females globally. It is marked by low sexual desire which leads to interpersonal difficulties and personal distress. In the United States, the disorder affects about 15 million women of which about a third of these are yet to hit menopause.

Currently, there is already a product in the market to treat this condition but there exists low patient awareness and understanding with just a scant number of women seeking treatment for the disorder. A study conducted indicated that approximately 95% of HSDD sufferers were unaware that the condition was treatable. A majority showed a willingness to try a drug like Rekynda if their doctor so recommended.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) fell by 35.57% to close the day at $23.00 a share on Monday.

Follow Palatin Technologies Inc (NYSEMKT:PTN)
Trade (NYSEMKT:PTN) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.

Loading Comments...